Pharmaceutical sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. Clinical Trials
Studies where Shenzhen Salubris Pharmaceuticals Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 15Hypertension
An Extension Trial of GW 906 in Participants With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
- Trial name
- NCT07879755
- Testing
- GW906
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.
- Trial name
- NCT07835984
- Testing
- GW906
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Elevated Lipoprotein(a)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk.
- Trial name
- NCT07729475
- Testing
- SAL0137 Dose 1, SAL0137 Dose 2, SAL0137 Dose 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hyperlipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAL0167 following single and multiple dose administration in healthy participants.
- Trial name
- NCT07722299
- Testing
- SAL0167 group
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Uncontrolled Hypertension
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
- Trial name
- NCT07654140
- Testing
- SAL0140
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Chronic Kidney Disease
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).
- Trial name
- NCT07647133
- Testing
- SAL0140 Tablets
- Where
- 2 sites in China
- Volunteers
- 249 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Primary Aldosteronism
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
- Trial name
- NCT07646535
- Testing
- SAL0140 Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Postmenopausal Women With Osteoporosis
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
- Trial name
- NCT07579936
- Testing
- SAL056 56.5μg, Intervention Group 1, Intervention Group 2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Primary Hypertension
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate…
- Trial name
- NCT07486453
- Testing
- Sequence A T-R-T-R, Sequence B R-T-R-T
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Osteoporosis
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
Primary objective of this study is to evaluate the similarity in pharmacokinetic characteristics between SAL023 Injection and Italy-manufactured Evenity.
- Trial name
- NCT07384104
- Testing
- SAL0123, Romosozumab
- Where
- China
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.